Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

Summary

This is a multicentre, double blind, randomized placebo controlled trial to assess the effect of LF-PB on seroma formation in women with breast cancer undergoing Axillary Lymph Node Dissection (ALND). Recruited patients will be randomly assigned to receive LF-PB 30 mg or placebo.

Timeline

Start

2015-10-22

Primary completion

2016-07-19

Completion

2016-07-19

Drugs

Indications

No indication recorded.